Aggarwal Shailesh, Mani Sweatha, Balasubramanian Abirami, Veluswami Keerthana, Rao Sudipta
Department of Internal Medicine, Jagadguru Sri Shivarathreeshwara Medical College, Mysore, IND.
Internal Medicine, K.A.P. Viswanatham Government Medical College, Tiruchirappalli, IND.
Cureus. 2024 Jul 9;16(7):e64165. doi: 10.7759/cureus.64165. eCollection 2024 Jul.
Acromegaly is a rare disease caused mainly by pituitary adenoma, which results in elevated growth hormone (GH) levels and its primary mediator, insulin-like growth factor (IGF-1). The condition causes various complications, including cardiovascular, respiratory, neuropsychiatric, metabolic, and gastrointestinal complications, which affect the patient's quality of life. Metabolically, there has been an increased incidence of acromegaly-associated diabetes mellitus (DM), IGF-1 being the primary mediator, affecting the patient's overall morbidity/mortality and associated surge in cardiovascular events. In the current state of medicine, both nonpharmacologic and pharmacologic approaches in managing acromegaly-associated DM are validated, having their own individualistic positive or negative impact on glucose metabolism. This review article has compiled studies to demonstrate a link between acromegaly. It summarises the existing data on acromegaly associated with DM, explicitly understanding the effect of various medical treatments on glucose homeostasis.
肢端肥大症是一种主要由垂体腺瘤引起的罕见疾病，它会导致生长激素（GH）水平及其主要介质胰岛素样生长因子（IGF-1）升高。这种疾病会引发各种并发症，包括心血管、呼吸、神经精神、代谢和胃肠道并发症，这些都会影响患者的生活质量。在代谢方面，肢端肥大症相关糖尿病（DM）的发病率有所上升，IGF-1是主要介质，影响患者的总体发病率/死亡率以及心血管事件的相关激增。在当前医学状况下，管理肢端肥大症相关糖尿病的非药物和药物方法均已得到验证，它们对葡萄糖代谢有各自独特的正面或负面影响。这篇综述文章汇集了多项研究以证明肢端肥大症之间的联系。它总结了与糖尿病相关的肢端肥大症的现有数据，明确了解各种医学治疗对葡萄糖稳态的影响。
